Patents Assigned to Amazentis SA
-
Patent number: 12220424Abstract: A composition comprising: a) nicotinamide riboside and b) a urolithin which is a compound of formula (I) or a salt thereof: wherein: A, B, C and D are each independently selected from H and OH; W, X and Y are each independently selected from H and OH; and Z is selected from H and OH. The compositions are useful as medicaments, for example for treating muscle-related pathological conditions, neurodegenerative diseases, and/or mitochondrial diseases and as dietary supplements, functional foods and beverages, and specialised nutrition or medical foods.Type: GrantFiled: October 8, 2021Date of Patent: February 11, 2025Assignee: Amazentis SAInventors: Penelope Andreux, Christopher L. Rinsch
-
Patent number: 12109190Abstract: Disclosed are compounds for use in raising an immune response to an antigen and/or enhancing, modulating or augmenting an immune response to an antigen. Particularly the use of urolithins. The invention also relates to immune enhancers comprising urolithins, methods of using such immune enhancers and processes for the preparation of such immune enhancers. The invention also relates to the use of urolithins in methods for modulating stem cell function, for example, enhancing stem cell numbers, promoting stem cell regeneration and promoting stem cell differentiation.Type: GrantFiled: August 24, 2022Date of Patent: October 8, 2024Assignee: Amazentis SAInventors: Anurag Singh, Davide D'Amico, Penelope Andreux, William Blanco-Bose, Christopher L. Rinsch
-
Patent number: 12036205Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.Type: GrantFiled: January 14, 2022Date of Patent: July 16, 2024Assignee: Amazentis SAInventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Charles Thomas, Carmen Sandi, Johan Auwerx, Penelope Andreux, Richardus Houtkooper, Eija Pirinen, Laurent Mouchiroud, David Genoux
-
Patent number: 12030863Abstract: The invention provides compounds of formula (I) or salts thereof: wherein: A, B, C, D, W, X, Y and Z are as defined in the specification, and at least one of A, B, C, D, W, X, Y and Z is OR1; each R1 being independently H or C(?O)R2, and at least one R1 group being C(?O)R2; where each R2 is selected from: CHR3NHR4, where R4 is H and R3 is a group selected from CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, CH2Ph, CH2-3-(1H-indole), CH2CH2SCH3, CH2OH, CHOHCH3, CH2SH, CH2SeH and CH2PhpOH, wherein said R3 group can optionally be substituted by one or more groups selected from halogen, cyano, nitro, ORA or C1-C4 alkyl; or R3 and R4 together with the C and N atoms to which they are attached form a 5-membered heteroalkyl ring, wherein said heteroalkyl ring can optionally be substituted by one or more groups selected from halogen, cyano, nitro, ORA or C1-C3 alkyl, wherein RA is C1-C4 alkyl optionally substituted with one or more halogen, cyano or nitro groups.Type: GrantFiled: November 2, 2021Date of Patent: July 9, 2024Assignee: Amazentis SAInventors: Christopher L. Rinsch, Rune Andreas Ringom
-
Patent number: 11969408Abstract: The invention provides a compound of formula (I) wherein: A, B, C, D, W, X, Y and Z are each independently selected from H and OH; or a salt thereof; for use in the treatment and/or prophylaxis of a condition, disease or disorder in a subject, wherein the compound or salt is orally administered to a subject in a daily amount of from 2.8 to 6.6 mmol per day, over a period of at least 21 days. Also are provided are the compound of formula (I) for use in increasing mitophagy and/or autophagy, maintaining and/or improving muscle function and administration as a dietary, nutritional and/or health supplement.Type: GrantFiled: March 8, 2018Date of Patent: April 30, 2024Assignee: Amazentis SAInventors: Christopher Rinsch, Penelope Andreux, Anurag Singh
-
Patent number: 11931335Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.Type: GrantFiled: August 3, 2020Date of Patent: March 19, 2024Assignee: Amazentis SAInventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Laurent Mouchiroud, Dongryeol Ryu, Penelope Andreux, Johan Auwerx
-
Patent number: 11931336Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.Type: GrantFiled: May 19, 2021Date of Patent: March 19, 2024Assignee: Amazentis SAInventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Laurent Mouchiroud, Dongryeol Ryu, Penelope Andreux, Johan Auwerx
-
Patent number: 11925616Abstract: The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition.Type: GrantFiled: May 5, 2022Date of Patent: March 12, 2024Assignee: Amazentis SAInventors: Penelope Andreux, Christopher Rinsch, William Blanco-Bose
-
Patent number: 11903922Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.Type: GrantFiled: July 14, 2020Date of Patent: February 20, 2024Assignee: Amazentis SAInventors: Christopher Rinsch, William Blanco-Bose, Bernard Schneider, Charles Thomas, Carmen Sandi, Johan Auwerx, Penelope Andreux, Richardus Houtkooper, Eija Pirinen, Laurent Mouchiroud, David Genoux
-
Patent number: 11878964Abstract: The invention provides compositions comprising a source of protein and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition. The invention also provides kits comprising urolithin and protein.Type: GrantFiled: April 23, 2021Date of Patent: January 23, 2024Assignee: Amazentis SAInventors: Penelope Andreux, Christopher L. Rinsch, William Blanco-Bose
-
Patent number: 11634401Abstract: Disclosed are methods for preparing a salt of urolithin A and, in turn, urolithin A. The methods are advantageous for the large-scale preparation of urolithin A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 5, 2021Date of Patent: April 25, 2023Assignee: Amazentis SAInventors: Wolfgang Skranc, George Yiannikouros, Alexander Trofimov, Zhixing Shan, Christopher Goss
-
Patent number: 11426380Abstract: Disclosed are compounds for use in raising an immune response to an antigen and/or enhancing, modulating or augmenting an immune response to an antigen. Particularly the use of urolithins. The invention also relates to immune enhancers comprising urolithins, methods of using such immune enhancers and processes for the preparation of such immune enhancers. The invention also relates to the use of urolithins in methods for modulating stem cell function, for example, enhancing stem cell numbers, promoting stem cell regeneration and promoting stem cell differentiation.Type: GrantFiled: October 1, 2020Date of Patent: August 30, 2022Assignee: Amazentis SAInventors: Anurag Singh, Davide D'Amico, Penelope Andreux, William Blanco-Bose, Christopher L. Rinsch
-
Patent number: 11337957Abstract: The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition.Type: GrantFiled: June 15, 2020Date of Patent: May 24, 2022Assignee: Amazentis SAInventors: Penelope Andreux, Christopher Rinsch, William Blanco-Bose
-
Patent number: 11234960Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.Type: GrantFiled: March 11, 2015Date of Patent: February 1, 2022Assignee: Amazentis SAInventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Charles Thomas, Carmen Sandi, Johan Auwerx, Penelope Andreux, Richardus Houtkooper, Eija Pirinen, Laurent Mouchiroud, David Genoux
-
Patent number: 11180468Abstract: The invention provides compounds of formula (I) or salts thereof: wherein: A, B, C, D, W, X, Y and Z are as defined in the specification, and at least one of A, B, C, D, W, X, Y and Z is OR1; each R1 being independently H or C(?O)R2, and at least one R1 group being C(?O)R2; where each R2 is selected from: CHR3NHR4, where R4 is H and R3 is a group selected from CH3, CH2CH(CH3)2, CH(CH3)CH2CH3, CH2Ph, CH2-3-(1H-indole), CH2CH2SCH3, CH2OH, CHOHCH3, CH2SH, CH2SeH and CH2PhpOH, wherein said R3 group can optionally be substituted by one or more groups selected from halogen, cyano, nitro, ORA or C1-C4 alkyl; or R3 and R4 together with the C and N atoms to which they are attached form a 5-membered heteroalkyl ring, wherein said heteroalkyl ring can optionally be substituted by one or more groups selected from halogen, cyano, nitro, ORA or C1-C3 alkyl, wherein RA is C1-C4 alkyl optionally substituted with one or more halogen, cyano or nitro groups.Type: GrantFiled: January 13, 2020Date of Patent: November 23, 2021Assignee: Amazentis SAInventors: Christopher Rinsch, Rune A. Ringom
-
Patent number: 11166972Abstract: Disclosed are compositions comprising nicotinamide riboside and a urolithin. The compositions are useful as medicaments, for example, for treating muscle-related pathological conditions, neurodegenerative diseases, and/or mitochondrial diseases, and as dietary supplements, functional foods and beverages, and as specialized nutrition or medical foods.Type: GrantFiled: December 23, 2016Date of Patent: November 9, 2021Assignee: Amazentis SAInventors: Penelope Andreux, Christopher L. Rinsch
-
Patent number: 11166937Abstract: Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin A. In certain embodiments the compositions are presented in or as food products or nutritional supplements. These same compounds and compositions can also be used advantageously in generally healthy individuals to increase or maintain metabolic rate, decrease percent body fat, increase or maintain muscle mass, manage body weight, improve or maintain mental performance (including memory), improve or maintain muscle performance, improve or maintain mood, and manage stress.Type: GrantFiled: June 18, 2018Date of Patent: November 9, 2021Assignee: Amazentis SAInventors: Christopher L. Rinsch, William Blanco-Bose, Bernard Schneider, Charles Thomas, Carmen Sandi, Johan Auwerx, Penelope Andreux, Richardus Houtkooper, Eija Pirinen, Laurent Mouchiroud, David Genoux
-
Patent number: 11020373Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.Type: GrantFiled: June 27, 2013Date of Patent: June 1, 2021Assignee: Amazentis SAInventors: Christopher Lawrence Rinsch, William Blanco-Bose, Bernard Schneider, Laurent Mouchiroud, Dongryeol Ryu, Penelope Andreux, Johan Auwerx
-
Patent number: 10988453Abstract: The invention provides compositions comprising a source of protein and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition. The invention also provides kits comprising urolithin and protein.Type: GrantFiled: October 1, 2019Date of Patent: April 27, 2021Assignee: Amazentis SAInventors: Penelope Andreux, Christopher L. Rinsch, William Blanco-Bose
-
Patent number: 10906883Abstract: Disclosed are methods for preparing a salt of urolithin A and, in turn, urolithin A. The methods are advantageous for the large-scale preparation of urolithin A or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 27, 2019Date of Patent: February 2, 2021Assignee: Amazentis SAInventors: Wolfgang Skranc, George Yiannikouros, Alexander Trofimov, Zhixing Shan, Christopher Goss